Patent: 10,501,523
✉ Email this page to a colleague
Summary for Patent: 10,501,523
Title: | IL-8 level based method of predicting the outcome of colon cancer treatment |
Abstract: | The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer. |
Inventor(s): | Chiron-Blondel; Marielle (Paris, FR), Lambrechts; Diether (Leuven, BE), Magherini; Emmanuelle (Ris Orangis, FR), Thuillier; Vincent (Bures sur Yvette, FR) |
Assignee: | SANOFI (Paris, FR) |
Application Number: | 15/408,827 |
Patent Claims: | see list of patent claims |
Details for Patent 10,501,523
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2034-07-18 |
Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | 11/18/2011 | ⤷ Try a Trial | 2034-07-18 |
Regeneron Pharmaceuticals, Inc. | EYLEA | aflibercept | Injection | 125387 | 08/16/2018 | ⤷ Try a Trial | 2034-07-18 |
Sanofi-aventis U.s. Llc | ZALTRAP | ziv-aflibercept | Injection | 125418 | 08/03/2012 | ⤷ Try a Trial | 2034-07-18 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |